The University of Kansas Jayhawks basketball team will wear exclusive pairs of the Adidas Trae Young 2 this season.
The Jayhawks are the BIG 12 rivals of Young’s alma mater, the University of Oklahoma Sooners.
The University of Kansas is an Adidas school, and Young is one of the German footwear company's five athletes with a signature basketball shoe.
As Young is emerging as the face of Adidas basketball, it is only natural that the Jayhawks wear his shoes in the upcoming season.
When NCAA basketball teams began hosting their media days last month, several Kansas Jayhawks players wore a player-exclusive colorway of the Adidas Trae Young 2.
The Adidas Trae Young 2, Young's second signature shoe with Adidas, launches on November 1, 2022 and will cost $140 in adult sizes. Fans will be able to purchase the shoes on the Adidas website and at select retailers.


FAA to Pause Reagan National Airport Flights for Freedom 250 IndyCar Race
NAB Q3 Cash Earnings Rise 2% as Lower Credit Charges Boost Profit
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories
Trump Imposes New Tariffs on Drone Imports Over US Security Concerns
Oil Prices Steady as Strait of Hormuz Traffic Slows Amid US-Iran Conflict
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy
Los Angeles Mayor Says White House Must Reassure Fans Ahead of FIFA World Cup
World game at war: why some European nations have threatened a World Cup boycott
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised
JD Vance to Lead U.S. Presidential Delegation at Milano Cortina Winter Olympics Opening Ceremony
Trump to Host UFC Event at White House on His 80th Birthday
US Dollar Slips as Weak Retail Sales Reduce Fed Rate Hike Bets
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast
US Reviewing Visa Denial for Venezuelan Little League Team Barred from World Series
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 



